345 related articles for article (PubMed ID: 25217655)
1. The tell-tale heart: molecular and cellular responses to childhood anthracycline exposure.
Lindsey ML; Lange RA; Parsons H; Andrews T; Aune GJ
Am J Physiol Heart Circ Physiol; 2014 Nov; 307(10):H1379-89. PubMed ID: 25217655
[TBL] [Abstract][Full Text] [Related]
2. New signal transduction paradigms in anthracycline-induced cardiotoxicity.
Ghigo A; Li M; Hirsch E
Biochim Biophys Acta; 2016 Jul; 1863(7 Pt B):1916-25. PubMed ID: 26828775
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?
Sawyer DB; Peng X; Chen B; Pentassuglia L; Lim CC
Prog Cardiovasc Dis; 2010; 53(2):105-13. PubMed ID: 20728697
[TBL] [Abstract][Full Text] [Related]
4. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
Scully RE; Lipshultz SE
Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
[TBL] [Abstract][Full Text] [Related]
5. Cardiotoxicity of Cancer Treatments: Focus on Anthracycline Cardiomyopathy.
Nishi M; Wang PY; Hwang PM
Arterioscler Thromb Vasc Biol; 2021 Nov; 41(11):2648-2660. PubMed ID: 34587760
[TBL] [Abstract][Full Text] [Related]
6. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
Henriksen PA
Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
[TBL] [Abstract][Full Text] [Related]
7. Anthracycline Chemotherapy and Cardiotoxicity.
McGowan JV; Chung R; Maulik A; Piotrowska I; Walker JM; Yellon DM
Cardiovasc Drugs Ther; 2017 Feb; 31(1):63-75. PubMed ID: 28185035
[TBL] [Abstract][Full Text] [Related]
8. Circulating microRNAs: Potential Markers of Cardiotoxicity in Children and Young Adults Treated With Anthracycline Chemotherapy.
Leger KJ; Leonard D; Nielson D; de Lemos JA; Mammen PP; Winick NJ
J Am Heart Assoc; 2017 Apr; 6(4):. PubMed ID: 28377429
[TBL] [Abstract][Full Text] [Related]
9. Anthracycline and Peripartum Cardiomyopathies.
Cowgill JA; Francis SA; Sawyer DB
Circ Res; 2019 May; 124(11):1633-1646. PubMed ID: 31120822
[TBL] [Abstract][Full Text] [Related]
10. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes--a report from the Children's Oncology Group.
Blanco JG; Sun CL; Landier W; Chen L; Esparza-Duran D; Leisenring W; Mays A; Friedman DL; Ginsberg JP; Hudson MM; Neglia JP; Oeffinger KC; Ritchey AK; Villaluna D; Relling MV; Bhatia S
J Clin Oncol; 2012 May; 30(13):1415-21. PubMed ID: 22124095
[TBL] [Abstract][Full Text] [Related]
11. Exposure to anthracyclines during childhood causes cardiac injury.
Lipshultz SE
Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular status of childhood cancer survivors exposed and unexposed to cardiotoxic therapy.
Lipshultz SE; Landy DC; Lopez-Mitnik G; Lipsitz SR; Hinkle AS; Constine LS; French CA; Rovitelli AM; Proukou C; Adams MJ; Miller TL
J Clin Oncol; 2012 Apr; 30(10):1050-7. PubMed ID: 22393080
[TBL] [Abstract][Full Text] [Related]
13. Cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review.
Bryant J; Picot J; Levitt G; Sullivan I; Baxter L; Clegg A
Health Technol Assess; 2007 Jul; 11(27):iii, ix-x, 1-84. PubMed ID: 17610809
[TBL] [Abstract][Full Text] [Related]
14. Current Views on Anthracycline Cardiotoxicity in Childhood Cancer Survivors.
Sadurska E
Pediatr Cardiol; 2015 Aug; 36(6):1112-9. PubMed ID: 25939787
[TBL] [Abstract][Full Text] [Related]
15. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
[TBL] [Abstract][Full Text] [Related]
16. Cranial irradiation as an additional risk factor for anthracycline cardiotoxicity in childhood cancer survivors: an analysis from the cardiac risk factors in childhood cancer survivors study.
Landy DC; Miller TL; Lipsitz SR; Lopez-Mitnik G; Hinkle AS; Constine LS; Adams MJ; Lipshultz SE
Pediatr Cardiol; 2013 Apr; 34(4):826-34. PubMed ID: 23080542
[TBL] [Abstract][Full Text] [Related]
17. Altered Peripheral Blood Gene Expression in Childhood Cancer Survivors With Anthracycline-Induced Cardiomyopathy - A COG-ALTE03N1 Report.
Singh P; Shah DA; Jouni M; Cejas RB; Crossman DK; Magdy T; Qiu S; Wang X; Zhou L; Sharafeldin N; Hageman L; McKenna DE; Armenian SH; Balis FM; Hawkins DS; Keller FG; Hudson MM; Neglia JP; Ritchey AK; Ginsberg JP; Landier W; Bhatia R; Burridge PW; Bhatia S
J Am Heart Assoc; 2023 Oct; 12(19):e029954. PubMed ID: 37750583
[TBL] [Abstract][Full Text] [Related]
18. Genotyping the risk of anthracycline-induced cardiotoxicity.
Deng S; Wojnowski L
Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
[TBL] [Abstract][Full Text] [Related]
19. Effect of standard low-dose anthracycline chemotherapy on late congestive heart failure in breast cancer survivors aged between 50 and 59 at diagnosis: A nationwide study.
Chung IY; Lee JW; Moon HG; Shin KH; Han W; Son BH; Ahn SH; Noh DY
Breast; 2020 Oct; 53():125-129. PubMed ID: 32771950
[TBL] [Abstract][Full Text] [Related]
20. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
Barrett-Lee PJ; Dixon JM; Farrell C; Jones A; Leonard R; Murray N; Palmieri C; Plummer CJ; Stanley A; Verrill MW
Ann Oncol; 2009 May; 20(5):816-27. PubMed ID: 19153118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
